Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia

European Journal of Anaesthesiology

Volumn 21, Issue 2, 2004, Pages 151-157

  Ginz, Hans F ^a,b   Girard, T ^a   Censier, K ^a   Urwyler, A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Alkaloids, ryanodine; Muscle contraction; Pathological processes, malignant hyperthermia

Indexed keywords

ALKALOID; CAFFEINE; HALOTHANE; RYANODINE;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCLE CONTRACTION; TASK PERFORMANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANESTHETICS, INHALATION; BIOPSY; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HALOTHANE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SKELETAL; RETROSPECTIVE STUDIES; RYANODINE; TIME FACTORS;

EID: 0842327340     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0265021504002121     Document Type: Article

References (30)

1. Iaizzo PA, Klein W, Lehmann-Horn E Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflugers Arch 1988; 411: 648-653.
2. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779.
3. Ball SP, Johnson KJ. The genetics of malignant hyperthermia. J Med Genet 1993; 30: 89-93.
4. Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23: 4-17.
5. Manning BM, Quane KA, Ording H, et al. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 1998; 62: 599-609.
6. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988; 263: 9310-9315.
7. MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 559-561.
8. McCarthy TV, Healy JM, Heffron JM, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343: 562-564.
9. Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448-451.
10. Robinson RL, Monnier N, Wolz W, et al. A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum Mol Genet 1997; 6: 953-961.
11. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia susceptibility. Br J Anaesth 1984; 56: 1267-1269.
12. Jenden DJ, Fairhurst AS. The pharmacology of ryanodine. Pharmacol Rev 1969; 21: 1-25.
13. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988; 263: 9310-9315.
14. 2+ release channel complex of skeletal muscle sarcoplasmic reticulum. Evidence for a cooperatively coupled, negatively charged homotetramer. J Biol Chem 1989; 264: 16776-16785.
15. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br J Anaesth 1991; 66: 611-613.
16. Hopkins PM, Ellis FR, Halsall PJ. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders. Br J Anaesth 1993; 70: 397-401.
17. Hopkins PM, Hartung E, Wappler F and the European Malignant Hyperthermia Group. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. Br J Anaesth 1998; 80: 389-394.
18. Hartung E, Koob M, Anetseder M, et al. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-, caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Acta Anaesthesiol Scand 1996; 40: 437-444.
19. Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth Analg 1996; 82: 1230-1236.
20. Lenzen C, Roewer N, Wappler F, et al. Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients. Br J Anaesth 1993; 71: 242-246.
21. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-966.
22. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test. A report from the North American Hyperthermia Registry. Anesthesiology 1998; 88: 579-588.
23. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.
24. Glantz SA. Primer of Biostatistics, 5th edn. New York, NY, USA: McGraw-Hill, 2001.
25. Sudo RT, Nelson TE. Changes in ryanodine-induced contractures by stimulus frequency in malignant hyperthermia susceptible and malignant hyperthermia nonsusceptible dog skeletal muscle. J Pharmacol Exp Ther 1997; 282: 1331-1336.
26. Phillips MS, Fujii J, Khanna VK, et al. The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 1996; 34: 24-41.
27. Girard T, Urwyler A, Censier K, Mueller CR, Zorzato F, Treves S. Genotype-phenotype comparison of the Swiss malignant hyperthermia population. Hum Mutat 2001; 18: 357-358.
28. Robinson RL, Brooks C, Brown S, et al. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat 2002; 20: 88-97.
29. Ording H, Islander G, Bendixen D, Ranklev-Twetman E. Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility. Anesth Analg 2000; 91: 452-457.
30. Loke JCP, MacLennan DH. Bayesian modeling of muscle biopsy contracture testing for malignant hyperthermia susceptibility. Anesthesiology 1998; 88: 589-600.